Evidence map›Paper›PMID 40251391›Full record

ArticleOncogene2025

Cancer stem cells-derived exosomal TSPAN8 enhances non-stem cancer cells stemness and promotes malignant progression in PDAC.

Xiaoyi Yang, Rujiao Liu, Juan Jin, Jingxuan Xv, Jiahao Wu, Yijie Jin, Yaya Zhang, Shan Chen, Bin Sun, Mou-Bin Lin and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Regulation of Cancer Stem Cells in the Tumor Microenvironment.Cancer heterogeneity and plasticity · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xiaoyi Yang *Department of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Rujiao Liu *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Juan Jin *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jingxuan XvDepartment of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jiahao WuDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Yijie JinDepartment of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yaya ZhangDepartment of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shan ChenDepartment of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Bin SunCenter for Clinical Research and Translational Medicine, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.
Mou-Bin LinCenter for Clinical Research and Translational Medicine, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.
Wumaier ReziyaDepartment of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Junjian LiDepartment of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0001-7970-4163
Haoyu SunDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Hongxia WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID http://orcid.org/0000-0003-3481-6940
Bo YuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. yudky@163.com.ORCID http://orcid.org/0000-0001-6039-4249
Guangjian FanDepartment of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. gjfan@shsmu.edu.cn.ORCID http://orcid.org/0000-0003-0684-1380
Wenting LiuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. liuwenting1015@163.com.ORCID http://orcid.org/0009-0001-6563-1116

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells (CSC) play a crucial role in pancreatic ductal adenocarcinoma (PDAC) progression and therapeutic resistance. However, the underlying mechanisms and potential targeted treatment strategies remain poorly understood. In this study, we employed single-cell RNA sequencing and exosomal profiling, identifying TSPAN8-enriched exosomes secreted by CSC, which are associated with poor survival rates in PDAC patients. They enhanced stemness in the surrounding non-stem cancer cells (NSCC) by activating the Sonic Hedgehog (Hh) signalling pathway. This exosomal TSPAN8-Hh signalling axis significantly increases the clonogenic ability, invasiveness, and chemoresistance of PDAC cells. Furthermore, TSPAN8-enriched exosomes promoted a higher stem cell frequency, tumourigenicity, and tumour growth rate in vivo, confirming their critical roles in PDAC malignant progression. Our findings underscore the importance of TSPAN8-enriched exosomes for CSC-NSCC communication during PDAC progression.

Indexed as

Carcinoma, Pancreatic DuctalExosomesNeoplastic Stem CellsPancreatic NeoplasmsTetraspaninsAnimalsCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticHedgehog ProteinsHumansMiceSignal TransductionHedgehog ProteinsTetraspaninsTSPAN8 protein, human

Identifiers

PMID40251391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.